Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk by Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla, Víctor Sapena, Zoe Mariño, Sabela Lens, Ramón Vilana, Isabel Nuñez, Anna Darnell, Ernest Belmonte, Ángeles García-Criado, Alba Díaz, Marco Sanduzzi-Zamparelli, Carla Fuster, Sergio Muñoz-Martínez, Carmen Ayuso, Jordi Rimola, Alejandro Forner, Alexandre Soler, Ferran Torres, José Ríos, Jordi Bruix, Andrew M. Moon, Xavier Forns, María Reig

“…Abstract Background The eradication of the Hepatitis C Virus (HCV) reduce the risk of liver cancer (LC), but lifestyle changes after cure may counterbalance its benefit. …”
Get full text

Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C by V. T. Ivashkin, V. P. Chulanov, N. A. Mamonova, M. V. Maevskaya, M. S. Zharkova, I. N. Tikhonov, P. O. Bogomolov, E. V. Volchkova, A. S. Dmitriev, O. O. Znojko, E. A. Klimova, K. V. Kozlov, I. E. Kravchenko, E. Yu. Malinnikova, R. V. Maslennikov, M. I. Mikhailov, K. E. Novak, I. G. Nikitin, V. E. Syutkin, E. V. Esaulenko, A. A. Sheptulin, E. N. Shirokova, N. D. Yushchuk

Subjects: “…hepatitis c…”
Get full text

RF-PSSM: A Combination of Rotation Forest Algorithm and Position-Specific Scoring Matrix for Improved Prediction of Protein-Protein Interactions Between Hepatitis C Virus and Human by Xin Liu, Yaping Lu, Liang Wang, Wei Geng, Xinyi Shi, Xiao Zhang

Subjects: Get full text

A single-site randomized controlled trial of partner navigation to HCV treatment for people who inject drugs: a study protocol for the You’re Empowered for Treatment Initiation (YE... by Meghan D. Morris, Judy Y. Tan, Claire C. McDonell, Maia Scarpetta, Tiffany N. Nguyen, Jennifer C. Price, Torsten B. Neilands

Subjects: “…Hepatitis C…”
Get full text

Computer analysis of regulation of hepatocarcinoma marker genes hypermethylated by HCV proteins by E. A. Antropova, T. M. Khlebodarova, P. S. Demenkov, A. S. Venzel, N. V. Ivanisenko, A.  D.  Gavrilenko, T.  V. Ivanisenko, A. V. Adamovskaya, P. M. Revva, I. N. Lavrik, V. A. Ivanisenko

Subjects: Get full text

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

“…IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. …”
Get full text

Molecular-genetic pathways of hepatitis C virus regulation of the expression of cellular factors PREB and PLA2G4C, which play an important role in virus replication by E. L. Mishchenko, A. A. Makarova, E. A. Antropova, A. S. Venzel, T. V. Ivanisenko, P. S. Demenkov, V. A. Ivanisenko

Subjects: “…hepatitis c virus…”
Get full text

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy by Eric M Yoshida, Morris Sherman, Vincent G Bain, Curtis L Cooper, Marc Deschênes, Paul J Marotta, Samuel S Lee, Mel Krajden, Helga Witt-Sullivan, Robert J Bailey, Christopher Usaty, Kevork Peltekian, the Canadian Pegasys Study Group

“…BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.…”
Get full text

Hepatitis C Virus Seroconversion among Hiv-Positive Men Who Have Sex with Men with No History of Injection Drug Use: Results from a Clinical Hiv Cohort by Ann N Burchell, Sandra L Gardner, Tony Mazzulli, Michael Manno, Janet Raboud, Vanessa G Allen, Ahmed M Bayoumi, Rupert Kaul, Frank McGee, Peggy Millson, Robert S Remis, Wendy Wobeser, Curtis Cooper, Sean B Rourke

“…BACKGROUND: Internationally, there is a growing recognition that hepatitis C virus (HCV) may be sexually transmitted among HIV-positive men who have sex with men (MSM).…”
Get full text

Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egypt: a cost-effectiveness study by Giuseppe Indolfi, Diana M Gibb, Aya Mostafa, Sarah Pett, Yazdan Yazdanpanah, Sylvie Deuffic-Burban, Anthony E Ades, Karen Scott, Ali Judd, Nadia Hachicha-Maalej, Clotilde Lepers, Intira Jeannie Collins, Manal H El Sayed

“…Backgrounds and aims Pregnant women and children are not included in Egypt’s hepatitis C virus (HCV) elimination programmes. This study assesses the cost-effectiveness of several screening and treatment strategies for pregnant women and infants in Egypt.Design A Markov model was developed to simulate the cascade of care and HCV disease progression among pregnant women and their infants according to different screening and treatment strategies, which included: targeted versus universal antenatal screening; treatment of women in pregnancy or deferred till after breast feeding; treatment of infected children at 3 years vs 12 years. …”
Get full text

Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline: A Systematic Review and Meta-Analysis by Awad Al-Omari, Juthaporn Cowan, Lucy Turner, Curtis Cooper

“…BACKGROUND: Depression complicates interferon-based hepatitis C virus (HCV) antiviral therapy in 10% to 40% of cases, and diminishes patient well-being and ability to complete a full course of therapy. …”
Get full text

Role of alpha-fetoprotein in complex diagnostics of progressing course of chronic hepatitis B and C by I. A. Belavina, O. P. Dudanova

Subjects: Get full text

Risk of progression and the cause of mortality at chronic viral mixed-hepatitis by K. I. Yesmembetov, D. T. Abdurakhmanov, A. V. Odintsov, N. A. Mukhin

Subjects: Get full text

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients by Shigeru Yutani, Kazuomi Ueshima, Kazumichi Abe, Atsushi Ishiguro, Junichi Eguchi, Satoko Matsueda, Nobukazu Komatsu, Shigeki Shichijo, Akira Yamada, Kyogo Itoh, Tetsuro Sasada, Masatoshi Kudo, Masanori Noguchi

“…To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). …”
Get full text

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy by Curtis Cooper, Stephen Shafran, Susan Greenbloom, Robert Enns, John Farley, Nir Hilzenrat, Kurt Williams, Magdy Elkashab, Nabil Abadir, Manuela Neuman

“…BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.…”
Get full text

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

Subjects: Get full text

Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada) by Robert P Myers, Curtis Cooper, Morris Sherman, Richard Lalonde, Helga Witt-Sullivan, Magdy Elkashab, Paul Harris, Rob Balshaw, Christopher Usaty, Paul J Marotta

“…BACKGROUND: In patients chronically infected with the hepatitis C virus (HCV), it is not established whether viral outcomes or health-related quality of life (HRQoL) differ between individuals treated at academic or community centres.…”
Get full text

Observational pilot using a Data to Care intervention strategy to promote HCV re-engagement and cure for persons with HIV/HCV co-infection who are out of care by Maximilian Wegener, Deborah Gosselin, Ralph Brooks, Suzanne Speers, Merceditas Villanueva

Subjects: “…Hepatitis C virus (HCV)…”
Get full text

A 7-Amino Acid Peptide Mimic from Hepatitis C Virus Hypervariable Region 1 Inhibits Mouse Lung Th9 Cell Differentiation by Blocking CD81 Signaling during Allergic Lung Inflammation by Wanzhou Zhao, Conghao Tan, Xi Yu, Ruihe Yu, Qibing Mei, Yun Cheng

“…A 7-amino acid peptide (7P) of the hypervariable region 1 (HVR1) of hepatitis C virus has been identified as an important regulator in the type 2 cytokine (IL-4, IL-5, and IL-13) immune response. …”
Get full text

Bayesian Analysis of Complex Mutations in HBV, HCV, and HIV Studies by Bing Liu, Shishi Feng, Xuan Guo, Jing Zhang

Subjects: Get full text